Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan OTC ticker: 1795) today announced an asset purchase agreement under which Lotus Group will acquire IP assets and existing businesses of Evista® (Raloxifene) in 7 countries in APAC for the prevention and treatment of osteoporosis from Takeda Pharmaceutical for approximately US$ 22 million.
Leveraging the company’s strong sales and marketing capabilities, and experience in successfully promoting branded products in APAC markets, Lotus will take over the Evista® businesses in Korea, Hong Kong/Macau, Thailand and other South East Asian markets from April 2019. Formal closing of the deal is expected following the completion of MA transfers in these territories in early 2020.